Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin

British Journal of Haematology

Volumn 163, Issue 5, 2013, Pages 681-683

  Zinzani, Pier Luigi ^a   Derenzini, Enrico ^a   Pellegrini, Cinzia ^a   Celli, Monica ^a   Broccoli, Alessandro ^a   Argnani, Lisa ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Bendamustine; Brentuximab vedotin; Hodgkin lymphoma; Refractory; Relapsed

Indexed keywords

BENDAMUSTINE; BRENTUXIMAB VEDOTIN;

ADULT; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; CLINICAL EVALUATION; CLINICAL FEATURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HODGKIN DISEASE; HUMAN; LETTER; MALE; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT DURATION;

BENDAMUSTINE; BRENTUXIMAB VEDOTIN; HODGKIN LYMPHOMA; REFRACTORY; RELAPSED;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; COMBINED MODALITY THERAPY; DACARBAZINE; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MALE; NITROGEN MUSTARD COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY, ADJUVANT; RECURRENCE; SALVAGE THERAPY; VINBLASTINE; YOUNG ADULT;

EID: 84887606450     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12548     Document Type: Letter

References (10)

1. Bartlett, N.L. (2008) Modern treatment of Hodgkin lymphoma. Current Opinion in Hematology, 15, 408-414.
2. Böll, B., Borchmann, P., Topp, M.S., Hänel, M., Reiners, K.S., Engert, A. & Naumann, R. (2010) Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. British Journal of Haematology, 148, 480-482.
3. Corazzelli, G., Angrilli, F., D'Arco, A., Ferrara, F., Musto, P., Guarini, A., Cox, M.C., Stelitano, C., Storti, S., Iannitto, E., Falorio, S., Califano, C., Amore, A., Arcamone, M., De Filippi, R. & Pinto, A. (2013) Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma. British Journal of Haematology, 160, 207-215.
4. Ghesquières, H., Stamatoullas, A., Casanovas, O., Morschhauser, F., Gyan, E., Gabarre, J., Malphettes, M., Clément, L., Ferlay, C. & Brice, P. (2013) Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients. Leukemia & Lymphoma, doi: 10.3109/10428194.2013.776165.
5. Johnston, P.B., Inwards, D.J., Colgan, J.P., Laplant, B.R., Kabat, B.F., Habermann, T.M., Micallef, I.N., Porrata, L.F., Ansell, S.M., Reeder, C.B., Roy, V. & Witzig, T.E. (2010) A phase II trial of the oral mTor inhibitor everolimus in relapsed Hodgkin lymphoma. American Journal of Hematology, 85, 320-324.
6. Moskowitz, C.H., Kewalramani, T., Nimer, S.D., Gonzalez, M., Zelenetz, A.D. & Yahalom, J. (2004) Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. British Journal of Haematology, 124, 645-652.
7. Moskowitz, A.J., Perales, M.A., Kewalramani, T., Yahalom, J., Castro-Malaspina, H., Zhang, Z., Vanak, J., Zelenetz, A.D. & Moskowitz, C.H. (2009) Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. British Journal of Haematology, 146, 158-163.
8. Moskowitz, A.J., Hamlin, P.A., Perales, M.A., Gerecitano, J., Horwitz, S.M., Matasar, M.J., Noy, A., Palomba, M.L., Portlock, C.S., Straus, D.J., Graustein, T., Zelenetz, A.D. & Moskowitz, C.H. (2013) Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma. Journal of Clinical Oncology, 31, 456-460.
9. Younes, A., Oki, Y., Bociek, R.G., Kuruvilla, J., Fanale, M., Neelapu, S., Copeland, A., Buglio, D., Galal, A., Besterman, J., Li, Z., Drouin, M., Patterson, T., Ward, M.R., Paulus, J.K., Ji, Y., Medeiros, L.J. & Martell, R.E. (2011) Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. The Lancet Oncology, 12, 1222-1228.
10. Zinzani, P.L., Viviani, S., Anastasia, A., Vitolo, U., Luminari, S., Zaja, F., Corradini, P., Spina, M., Brusamolino, E., Gianni, A.M., Santoro, A., Botto, B., Derenzini, E., Pellegrini, C. & Argnani, L. (2013) Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: Italian experience and results of the use in the daily clinic outside clinical trials. Haematologica, 98, 1232-1236.